Cancer Therapy Evaluation Program
| Type | Program |
|---|---|
| Sponsor Organization | National Cancer Institute |
| Top Organization | N/A |
| Creation Legislation | National Cancer Act of 1971 |
| Website | Website |
| Purpose | To facilitate the development of new cancer treatments by coordinating and funding clinical trials, managing the supply of investigational agents, and fostering collaborations between researchers, pharmaceutical companies, and academic institutions. The program aims to improve cancer treatment outcomes through innovative research and drug development. |
| Program Start | 1971 |
| Initial Funding | Part of the National Cancer Institute's budget |
| Duration | Ongoing |
| Historic | Yes |
Cancer Therapy Evaluation Program (CTEP) is a key component of the National Cancer Institute (NCI) dedicated to advancing cancer treatment through the coordination of clinical trials and the development of new therapeutic agents. It plays a pivotal role in bridging the gap between cancer research and clinical practice by managing drug development, trial oversight, and collaboration with industry partners.
Goals
- Accelerate the development and evaluation of novel cancer therapies.
- Enhance the efficiency of clinical trials for cancer treatments.
- Facilitate partnerships between NCI and pharmaceutical companies for drug development.
- Ensure the distribution of investigational agents for clinical research.
Organization
CTEP operates within the NCI’s Division of Cancer Treatment and Diagnosis (DCTD). It is structured into several branches, each with specific responsibilities, such as the Investigational Drug Branch for new drug development, the Clinical Investigations Branch for late-phase trials, and the Clinical Trials Monitoring Branch for ensuring trial compliance and data quality. The program is led by the CTEP Associate Director. Funding comes from the NCI's budget, which is part of the National Institutes of Health (NIH) appropriations.
The leader of the program holds the title of Associate Director of the Cancer Therapy Evaluation Program.
Partners
History
CTEP was established following the National Cancer Act of 1971, which aimed to intensify efforts against cancer. Since its inception, CTEP has evolved to meet the changing landscapes of cancer research, including a greater emphasis on personalized medicine, immunotherapy, and precision oncology. The program has adapted to include more collaborative models with industry and has expanded its scope to include not just drug development but also the integration of these drugs into effective treatment protocols.
Funding
CTEP's funding is integrated within the NCI's annual budget, with specific allocations for clinical trials, drug supply, and research collaborations. The initial funding was part of the broader NCI funding post-1971, and it continues to be supported without a defined end, reflecting its ongoing role in cancer research.
Implementation
CTEP implements its mission through the oversight of clinical trials from inception to completion, managing the supply chain for investigational drugs, and through various programs like the NCI Experimental Therapeutics (NExT) for prioritizing new agents. It does not have a defined end date, as it is central to NCI's long-term strategy against cancer.
Related
External links
- https://ctep.cancer.gov/
- wikipedia:Cancer Therapy Evaluation Program
Social media
- No specific social media accounts for CTEP, but updates might be shared through NCI's official channels.
References
"Cancer Therapy Evaluation Program". https://ctep.cancer.gov/.